San Diego startup CURx has paid an undisclosed sum to license an antiobitic developed by Gilead ($GILD), planning to launch a Phase III trial on the drug to treat lung infections in cystic fibrosis patients. The drug, a combination of fosfomycin and tobramycin, is designed to fight Pseudomonas aeruginosa infection, and, after a promising Phase II in CF patients, CURx figures it has a shot at approval. This is the inlicensing company's second deal, following a $21 million deal with Ligand ($LGND) to get its hands on a seizure medication. News